Sign in
Subscribe
    • Stock Lists
      arrow_drop_down
      • Longevity Stocks
      • COVID-19 Stocks
    • Longevity Trial Tracker
    • Newsletter
    • Resources
      arrow_drop_down
      • Events
      • Supporters
    • About
    Subscribe

    Recursion Pharmaceuticals

    AI/ML cell imaging for drug discovery. Senolytics.

    • Profile
    • prev
    • next
    • Bookmark
    • Website
    • Share
    • prev
    • next
    $
    $0.0000
    $0.0000
    0.00%

    Marketcap: $0.0000
    Volume: 0.0000

    Recursion Pharmaceuticals, Inc.
    Symbol: RXRX
    Employees: 500
    Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
    Website https://www.recursion.com

    LongevityMarketcap.com 2021.

      • Facebook
      • Twitter
      • WhatsApp
      • Telegram
      • LinkedIn
      • Tumblr
      • VKontakte
      • Mail
      • Copy link